2 results
Approved WMOCompleted
The purpose of this clinical investigation is to verify the efficacy and safety of the CVRx Neo Baroreflex Activation Therapy System in subjects who qualify for the implantation for a Baroreflex Activation Therapy System.
DDAVP treatment combined with FVIII clotting factor concentrates in patients with mild hemophilia A.
Primary objectives:To assess the proportion of non-severe hemophilia A patients within FVIII target levels with the DDAVP and FVIII concentrate combination treatment in the first 72 hours after the start of combination treatment, without adding off-…